Peripheral artery disease is an atherosclerotic disease of the lower extremities associated with high cardiovascular mortality. Management of this condition may include lifestyle modifications, medical management, endovascular repair, or surgery. The medical approach to peripheral artery disease is multifaceted and includes cholesterol reduction, antiplatelet therapy, anticoagulation, peripheral vasodilators, blood pressure management, exercise therapy, and smoking cessation. Adherence to this regimen can reduce limb-related complications like critical limb ischemia and amputation, as well as systemic complications of atherosclerosis like stroke and myocardial infarction. Relative to coronary artery disease, peripheral artery disease is an undertreated condition. In this article, we explore the evidence behind medical therapies for the management of peripheral artery disease.
P eripheral artery disease (PAD) is a chronic, atherosclerotic disease of the peripheral vasculature resulting in limb-associated complications such as intermittent claudication, ischemic rest pain, ischemic ulcer, gangrene, and functional impairment. Sequelae requiring amputation carries a mortality of ≤50% at 1 year. 1 While limb complications themselves are destructive, PAD is often a harbinger of obstructive atherosclerotic disease elsewhere, including the cerebral and coronary vasculature. Indeed, patients with PAD have an increased rate of ischemic stroke, myocardial infarction (MI), and cardiovascular death. [2] [3] [4] Furthermore, patients with coronary artery disease (CAD) and PAD have a much higher risk of cardiovascular mortality than CAD alone. 5, 6 Importantly, PAD is a significant burden for patients in terms of quality of life and financial wellbeing. 7 PAD is a relatively common condition with 220 million people affected globally and an increasing prevalence worldwide. 8 A number of therapies exist for the treatment of PAD, including those directed toward management of claudication symptoms, secondary prevention of cardiovascular complications, and limb salvage therapies. Treatment strategies can be subdivided into lifestyle modification, medical management, endovascular therapies, and surgical interventions. The purpose of this review is to examine the medical management for the treatment of PAD, which primarily include cholesterol reduction, antiplatelet therapy, anticoagulation, peripheral vasodilators, blood pressure control, smoking cessation, and exercise therapy. Despite the severity of this condition, patients with PAD are dramatically undertreated relative to their CAD counterparts with comparatively few trials directly assessing the efficacy of medical interventions. 9 In particular, blacks who have a high burden of disease are less likely to receive evidence-based treatment, potentially resulting in higher rates of complications. [10] [11] [12] In addition to a discussion of the evidence base for current PAD medical management, this review seeks to increase awareness of this disparity to improve PAD outcomes in the black community.
CHOLESTEROL REDUCTION
Elevated lipids and lipoproteins including total cholesterol, non-HDL (high-density lipoprotein) cholesterol, and LDL (low-density lipoprotein) cholesterol (LDL-C) are associated with an increased risk of cardiovascular disease, and PAD is no exception. [13] [14] [15] [16] [17] Contemporary research on statins, ezetimibe, and more recently PCSK9 inhibitors indicates that lowering lipids and, in particular, LDL-C to the lowest possible target greatly improves cardiovascular outcomes. [18] [19] [20] The American College of Cardiology (ACC)/American Heart Association (AHA) considers PAD to be equivalent to a history of MI or stroke with respect to cholesterol-lowering therapies. 14, 15, 17 The ACC/AHA recommends all patients with symptomatic PAD to be on high-intensity statin. In addition, individuals with PAD and another major atherosclerotic cardiovascular disease event (or 2 minor risk factors) should be treated to an LDL-C of <70 with a class I recommendation. 14, 15 Emerging evidence showing lower risk of ischemic events with the use of icosapent ethyl in REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl-Intervention Trial) suggests triglyceride reduction is effective for patients with cardiovascular disease, and future work may apply specifically to PAD. 21 
Statin Therapy
Statin therapy is by far the most well-recognized cholesterol-lowering therapy in the management of PAD. While the Scandinavian Simvastatin Survival Study Group had previously shown the mortality benefits of simvastatin in CAD, a secondary post hoc analysis of these data provided the first randomized trial data that statin therapy could be used to treat PAD. With a decreased incidence of carotid bruit and claudication in the simvastatin group over the median 5.4-year follow-up period, statin therapy appeared to suppress progression of this disease. 22 Later studies would detail statin benefits and provide more definitive evidence for its use in PAD.
The Heart Protection Study Collaborative Group provided the first randomized controlled trial data on statin therapy in PAD. Moderate-intensity statin therapy with simvastatin reduced peripheral vascular events (defined as noncoronary revascularization, amputation, aneurysm repair, and death from PAD) by 17% in a prespecified PAD group. 23 However, PAD was not defined by rigorous contemporary standards. Claudication and amputation did not require ankle-brachial index measurement or endovascular studies to confirm the definition of symptomatic PAD. Furthermore, aneurysm repair was included in the PAD and vascular event definitions as well. Since the Heart Protection Study, multiple retrospective studies corroborated the finding that statin therapy reduces the rate of amputation with relative risk reductions between 18% and 35%. 2, 24, 25 In a 2013 retrospective cohort study of diabetic patients with and without PAD, Sohn et al 24 compared outcomes for patients taking statins with those taking nonstatin lipid-lowering agents such as fibrates, bile acid sequestrants, nicotinic acid, and cholesterol absorption inhibitors (including ezetimibe) and found that those patients taking nonstatin lipid therapy did not share a reduction in lower extremity amputation rates. There was also a dose response with respect to statin intensity with high-intensity statin therapy resulting in a greater reduction of limb loss than moderateintensity therapy in a recent observational cohort study including both symptomatic and asymptomatic patients with PAD. 26 Statin therapy addresses both limb specific and systemic complications from PAD. The Heart Protection Study showed that irrespective of a prior history of coronary, cerebrovascular disease, or cholesterol levels, statin therapy reduced the rate of all cardiovascular events in PAD, with a 30% reduction in coronary revascularization, a 21% reduction in major coronary events, and a 26% reduction in ischemic stroke. 23 The Reduction of Atherothrombosis for Continued Health Registry, which prospectively followed patients with symptomatic PAD over 4 years, made similar conclusions with a 17% lower risk of cardiovascular death, nonfatal MI, or nonfatal stroke. 2 The notion that statin therapy reduces the risk of vascular events outside the periphery is supported by meta-analyses. 27, 28 Despite robust evidence showing a reduction in vascular events, meta-analysis did not demonstrate an overall reduction in mortality. 27, 28 While current guidelines suggest the use of high-intensity statin therapy, much of the trial data accumulated on statins in PAD used moderate-intensity statin dosing. 14, 15 Ezetimibe According to the most recent ACC/AHA guidelines for cholesterol management, statin therapy may not be sufficient in patients at very high risk defined by a history of multiple atherosclerotic cardiovascular disease events or a single event and multiple medical comorbidities. 14 A substantial portion of the PAD population falls into this category. The ACC/AHA cholesterol guidelines recommend the use of ezetimibe in the management of veryhigh-risk patients with LDL-C >70 despite maximally tolerated statin therapy and select non-very-high-risk patients with similarly resistant cholesterol levels. There are few studies evaluating the use of this medication in patients with PAD. The IMPROVE-IT trial randomized patients with recent hospitalization for ACS to receive ezetimibe or placebo alongside moderate-intensity statin therapy. 19 High-risk patients, categorized by the Thrombolysis in Myocardial Infarction score, appeared to obtain the greatest reduction in future cardiovascular events from ezetimibe, and about 18% of these high-risk patients had PAD. 29 This suggests a benefit to the addition of ezetimibe to statin therapy though a specific analysis for patients with PAD has not been performed, and the patient population was limited to those with recent ACS. The benefit from ezetimibe may be dependent on the presence of statin therapy. A small randomized trial compared femoral artery plaque burden progression between symptomatic PAD patients assigned statin therapy, statin therapy plus ezetimibe, and ezetimibe alone. The ezetimibe-alone group showed progression of plaque burden where the other groups remained stable indicating that ezetimibe without statin therapy is not sufficient in the management of PAD. 30
PCSK9 Inhibitors
PCSK9 inhibitors represent a substantial innovation to lipid management. The FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) using evolocumab in patients with atherosclerotic disease and LDL >70 mg/dL contained patients both with and without PAD. Patients with PAD had an impressive 59% reduction in LDL-C with evolocumab resulting in a 3.5% absolute risk reduction in the primary end point of cardiovascular events (MI, death, stroke, hospitalization for unstable angina, and coronary revascularization) compared with a 1.6% absolute risk reduction in patients without PAD. 31, 32 Importantly, patients in a prespecified symptomatic PAD group also had a reduction of 42% in major adverse limb events: acute limb ischemia, major amputation, or urgent peripheral revascularization for ischemia. This reduction was seen regardless of the intensity of statin therapy without excess adverse events. 31 There have not yet been any studies to examine outcomes of other PCSK9 inhibitors in patients with PAD. A future trial set to complete in 2021 will assess a second PCSK9 inhibitor, alirocumab, in patients with PAD and evaluate for plaque regression. 33 Future reduction in prices may expand indications for use as current guidelines recommend using PCSK9 inhibitors sparingly as a result of their high cost.
ANTIPLATELET THERAPY
Platelet activity is instrumental to the development of complications from cardiovascular disease, and PAD is no exception. Not only is platelet adherence an initial step toward atherosclerotic disease but platelet activity is abnormal in PAD. PAD is associated with platelet hyperaggregability and increased adhesion with higher expression of surface protein, P-selectin. [34] [35] [36] This unique behavior in PAD combined with the central role platelets play in atherothrombotic complications is the rationale for its use in PAD, but antiplatelet therapy also has a key role in prevention of complications in cardiovascular disease as a whole. Despite known relationships between PAD, platelet activity, and CAD, large-scale trials investigating the benefits of antiplatelet therapy in patients with PAD were decades behind those related to CAD.
Aspirin
The presence or absence of PAD symptoms is a major defining feature of this condition with drastically different clinical outcomes. 37 The use of aspirin has been evaluated in both asymptomatic and symptomatic PAD. However, multiple trials failed to show a reduction in cardiovascular events for aspirin in patients with asymptomatic PAD, including the Aspirin for Asymptomatic Atherosclerosis Trial, which compared 100 mg aspirin to placebo in 3350 patients with a follow-up time of >8 years. 38, 39 These results are in line with emerging data suggesting that aspirin is not effective in primary prevention of cardiovascular mortality. 40, 41 Aspirin has been shown to be effective for symptomatic PAD. The first major data to suggest its utility in PAD was in 2002 with a meta-analysis of randomized trials from the Antithrombotic Trialists' Collaboration. Analysis was conducted on >9000 patients with PAD and showed a proportional reduction of 23% in serious vascular events: nonfatal MI, nonfatal stroke, or vascular death (P=0.004). 42 However, the trial included all antiplatelet agents including clopidogrel. More direct evidence came in 2007 with the CLIPS (Critical Leg Ischemia Prevention Study), which evaluated the use of low-dose aspirin (81 mg) in 366 patients with symptomatic and asymptomatic PAD and found a 64% relative risk reduction in major vascular events: ischemic stroke, MI, and vascular death (P=0.022). 43 Finally the use of antiplatelet therapy was directly validated in a PAD population, and the risk reduction was at least, in part, driven by a reduction in fatal and nonfatal MI (hazard ratio, 0.18 [95% CI, 0.04-0.82]; P=0.03). Interestingly, by the time the CLIPS trial was published comparing aspirin to placebo, the ACC/AHA had already categorized antiplatelet therapy as a class I indication for PAD based on previous meta-analysis. 44 The CLIPS trial was followed up by another meta-analysis including both symptomatic and asymptomatic patients with PAD. The primary end point of cardiovascular events occurred less often in the aspirin group but did not reach statistical significance 8.9% versus 11.0% (RR, 0.88 [95% CI, 0.76-1.04]), which may be as a result of the inclusion of asymptomatic patients in the analysis. 45 
Clopidogrel
The P2Y12 inhibitor clopidogrel has been compared with aspirin in the CAPRIE trial (Clopidogrel Versus Aspirin in Patients at Risk for Ischemic Events), which remains the only trial data with a subgroup analysis comparing these 2 antiplatelet agents. 46 The results were impressive: almost a 25% reduction in the primary end point of vascular death, nonfatal MI, or CVA in patients with clopidogrel over aspirin. Compared with the other subsets in the trial, the prespecified symptomatic PAD group benefited the most. The general population had only an 8.7% relative risk reduction. 46 Single-agent antiplatelet therapy is a 2016 ACC/AHA class Ia recommendation; however, the guidelines do not recommend clopidogrel over aspirin despite the results of this subgroup analysis. 15 
Ticagrelor
The newer P2Y12 inhibitor, Ticagrelor, debuted in patients with CAD in the PLATO trial, which randomized patients with ACS to either clopidogrel or ticagrelor and found that ticagrelor significantly reduced the incidence of major adverse cardiovascular events at 1 year without significantly increasing the rate of major bleeding. 47 A post hoc subgroup analysis of this patient population included patients with lower extremity PAD and found a similar 15% relative risk reduction in the composite primary end point. Furthermore, patients with PAD had a much higher rate of developing the primary end point, suggesting that benefit may be larger for this patient population should a trial be designed for patients with PAD. 48 In 2017, the EUCLID trial compared clopidogrel and ticagrelor in almost 14 000 symptomatic PAD patients to determine whether or not ticagrelor was the better agent in PAD. Despite high hopes for the newer P2Y12 inhibitor, the primary end point of cardiovascular death, MI, or ischemic stroke was not significantly different (10.6% versus 10.8%) between the 2 agents. The only secondary end point to reach significance was a 0.5% absolute risk reduction in ischemic stroke for patients taking ticagrelor. Patients with carotid or coronary revascularization and patients with coronary artery stenting appeared to receive some benefit, although the study was not powered to distinguish benefit in this specific population and the results were not significant. 49 
Dual Antiplatelet Therapy
With platelet activity so critical to the development of atherothrombotic events, dual antiplatelet therapy (DAPT) was also assessed in PAD. The CHARISMA trial compared DAPT to single antiplatelet therapy and included patients with PAD. The primary outcomes of the trial were stroke, death, bleeding, and MI, but the authors showed no significant difference in outcome between DAPT and single antiplatelet therapy in the general trial population. 50 However, a post hoc subgroup analysis on PAD patients alone showed DAPT therapy resulted in a statistically significant 15% relative risk reduction in the primary end point (2.3% versus 3.7%; hazard ratio, 0.63; P=0.028). There was no difference in severe, fatal, or moderate bleeding between the 2 groups. The trial included a mixture of both symptomatic (91.7%) and asymptomatic patients (8.4%). 51 DAPT was evaluated in the 2015 PEGASUS-TIMI 54 trial, which examined the use of ticagrelor and aspirin in patients with MI 1 to 3 years prior. The subgroup analysis of >1000 patients with symptomatic PAD at the time of enrollment showed an absolute risk reduction of 4.1% in the primary end point of cardiovascular death, stroke, or MI for patients on DAPT compared with aspirin and placebo. Importantly, this group also had a significant 35% relative risk reduction in critical limb ischemia (CLI; P=0.026) at the cost of increased major and minor bleeding events. 52 The 2016 ACC/AHA PAD guidelines provide a lower recommendation (class IIb) for use of DAPT with clopidogrel suggesting it might be considered for select patients but that providers should be cautious given the absence of substantial long-term evidence. 15 Since this recommendation, however, a meta-analysis cast doubt on the utility of DAPT in patients with symptomatic PAD for the prevention of death, MI, or stroke as the reduction in primary outcome did not reach significance (7.6% versus 8.9%; odds ratio, 0.84 [CI, 0.65-1.08]; P=0.18) and long-term DAPT was associated with increased risk of bleeding (1.47% versus 0.88%; odds ratio, 1.65 [CI, 1.23-2.21]; P=0.001). 53 
ANTICOAGULATION
Recent research suggests the pathogenesis of CLI, the most serious limb complication of PAD, is primarily an atherothromboembolic disease. In a landmark study by Narula et al, almost 3 quarters of arteries taken from amputated limbs secondary to CLI show luminal thrombi, two-thirds of which had no significant atherosclerotic lesions. These findings suggest a thrombi-dependent mechanism in the pathogenesis of many PAD and limbrelated complications since the identified stenosis was not secondary to a local atherosclerotic process. 54 Trial data from warfarin, and more recently rivaroxaban, suggest that anticoagulation may in fact prevent limb-related complications from PAD, as well as all cardiovascular morbidity and mortality.
Warfarin
Multiple trials have assessed the utility of warfarin anticoagulation for the prevention of complications, initially in patients with a history of ACS. The OASIS (Organization to Assess Strategies for Ischemic Syndromes)-II and WARIS-II trials found the combination of warfarin and aspirin was better than aspirin alone at preventing major adverse cardiovascular events in this patient population. 55, 56 These trials paved the way for evaluation of anticoagulation of patients with known PAD, but initial results were not as promising. The WAVE trial (Warfarin Antiplatelet Vascular Evaluation) investigated the use of warfarin anticoagulation in combination with aspirin for patients with symptomatic PAD (81.8% of the total trial population), subclavian disease, and carotid disease. The trial found no significant difference in the occurrence of major adverse cardiovascular events between patients receiving combination aspirin and warfarin therapy alone. 57 Furthermore, they found a significant increase in the amount of major bleeding events, including intracranial hemorrhage. A subanalysis of this trial did show site variation and poor compliance with an almost 30% rate of discontinuation of warfarin at follow-up so the possibility remained that the lack of efficacy was related to poor medication adherence.
Rivaroxaban
The development of factor Xa inhibitors such as rivaroxaban and apixaban is promising for a number of different applications. Its potential benefits include increased patient compliance and lower likelihood of major bleeding when compared with warfarin. [58] [59] [60] The COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies) published in late 2017 demonstrated improved mortality with low-dose rivaroxaban in combination with aspirin for patients with PAD. Lowdose rivaroxaban, 2.5 mg twice daily, is a regimen previously used in the ATLAS-TIMI 51 trial evaluating the use of rivaroxaban in patients with recent ACS with the finding that this dosage decreased mortality of patients with recent ACS over placebo. 61 COMPASS tested this medication in CAD, PAD, or both. The predetermined PAD subgroup included patients with symptomatic lower extremity disease (55.2% of subgroup), as well as carotid artery disease. The primary end point of cardiovascular death, stroke, or MI occurred in 4.1% in the aspirin and low-dose rivaroxaban group compared with 4.9% in the rivaroxaban-alone group and 5.4% in the aspirin-alone group for all patients including those with CAD. In those patients enrolled with PAD, the primary end point occurred in the aspirin and low-dose rivaroxaban group 5.1% of the time versus 6.9% of the time for the aspirin-alone group. A comparison of the rivaroxaban-alone group and the aspirin-alone group was not different. 62 Importantly, major adverse limb events occurred less often in patients with PAD taking rivaroxaban and aspirin than aspirin alone, though these events were uncommon (1% versus 2%). 63 As expected, both the rivaroxaban-plus-aspirin group and the rivaroxabanalone group had higher major bleeding events than the aspirin-alone group (3.1%, 2.8%, and 1.9%), though the impact of this adverse event was somewhat mitigated by no statistically significant increase in fatal bleeding or symptomatic intracranial bleeding between the rivaroxaban-plus-aspirin group and the aspirin-alone group (P=0.40). Patients ≥75 years of age with and without PAD did not have a significant reduction in the primary end point with low-dose rivaroxaban and aspirin, so providers should consider the use of anticoagulation in this geriatric population with caution. 62, 63 Low-dose rivaroxaban and aspirin combination therapy compares favorably to other effective PAD medications such as statins. The Heart Protection Study found a 22% relative risk reduction in the first major vascular event with moderate-intensity statin therapy while the COMPASS trial showed a 28% relative risk reduction in the primary outcome with thw use of low-dose rivaroxaban and aspirin. 23, 62, 63 Importantly, the primary end point of cardiovascular death, stroke, or MI occurred more often in the PAD group, once again highlighting the importance of maximizing effective therapies in this patient population.
PERIPHERAL VASODILATORS
Intermittent claudication represents peripheral ischemia distal to a stenosis in the setting of exertion. This supply-demand mismatch is often a result of the stenosis, thus insufficient vasodilatory response may result in symptoms that are relieved by rest. As such, peripheral vasodilators are potentially beneficial for claudication. Claudication itself is associated with functional decline, and thus improvement of this symptom should be a focus of providers. 64 The ACC/AHA guidelines include a class IA recommendation cilostazol in the treatment of symptomatic claudication. 15 
Cilostazol
Multiple trials have evaluated the utility of this medication for the treatment of symptomatic PAD. A systematic Cochrane Review of 15 trials concluded that cilostazol increases exercise tolerance compared with placebo. Eight of the trials reviewed could be compared on the basis of walking distance before the onset of claudication symptoms with 100 mg twice daily improving the weighted mean walking distance by 31.41 m ([95% CI, 22.38-40.45 m] P<0.00001). No difference in absolute mortality was appreciated though there were a small number of events in the trials. 65, 66 For comparison, a Cochrane Review found supervised exercise programs resulted in ≈150 m increase in walking distance or ≈30% to 35% increase, which was sustained at 6 months. 67 The improvement seen with cilostazol is subtle in comparison to supervised exercise programs. Incidence of headache, palpitations, and diarrhea are relatively common adverse effects. 68 More importantly, cilostazol is contraindicated in patients with heart failure as medications in this class may be associated with excess mortality. 69 Medical comorbidities like diabetes mellitus, hyperlipidemia, and hypertension are common in patients with PAD, so patients are frequently taking a number of medications. The side effect profile, heart failure contraindication, pill burden, and subtle benefit are all reasons cilostazol is infrequently used and should only be considered in otherwise medically optimized patients with refractory claudication who are able to tolerate the medication.
BLOOD PRESSURE MANAGEMENT
The 2016 ACC/AHA guidelines for lower extremity peripheral artery disease gives antihypertensive therapy a class IA recommendation for patients with peripheral artery disease and suggests that blood pressure management should be in accordance with current hypertension guidelines given significant cardiovascular mortality in this population. 15 According to current 2017 ACC/ AHA guidelines on hypertension, antihypertensive medication is recommended for patients with CVD and systolic pressure >130 or diastolic blood pressure >80. 70 However, a post hoc analysis of INVEST (International Verapamil-SR/Trandolapril Study), which included 2699 patients with both PAD and CAD, showed a j-shaped curve of mortality and blood pressure. For patients with PAD, mortality benefits were seen with a treated systolic blood pressure of 135 to 145 mm Hg and treated diastolic pressure of 60 to 90 mm Hg with higher mortality observed in low systolic and high systolic blood pressure ranges, supporting the paradigm that blood pressure management in PAD is a balance between limb perfusion and risk factor modification. 71 As a result, the European Society of Cardiology recommends lowering blood pressure in patients with PAD to <140/90 with a class IA recommendation. 72 Perhaps future trials will elucidate the ideal blood pressure range for patients with PAD.
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
The use of ACE (angiotensin-converting enzyme) inhibitors as an antihypertensive class has been evaluated for patients with PAD with some evidence to suggest benefit of this medication over other antihypertensives. In 2000, the HOPE trial (Heart Outcomes Prevention Evaluation) compared the use of ramipril to placebo in patients with CVD without heart failure with reduced ejection fraction. The study included 3099 patients with PAD defined as low ankle-brachial index. A post hoc analysis found that patients with PAD benefited from a significant reduction in the primary outcome of cardiovascular death, MI, or stroke as did those patients without peripheral vascular disease. Patients entering the trial had a similar blood pressure of 139/79 mm Hg in both groups. The mean blood pressure was 133/76 mm Hg in the ramipril group and 137/78 mm Hg in the placebo group at 1 month and maintained a similarly small reduction throughout the duration of the study. 73 The relatively small reduction in blood pressure in the treatment arm implies there may be an additional benefit to the use of ACE inhibitors over other antihypertensives. 74 The ONTARGET trial (Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial) compared angiotensin receptor blocker (ARB) telmisartan to ramipril or combination ARB and ACE inhibitor therapy and found no significant difference in the primary end point of cardiovascular mortality, MI, stroke, or hospitalization for heart failure between all 3 groups but a higher rate of adverse events in the combination group. The trial included 3468 patients with PAD. 75 Several prospective and retrospective studies have shown a reduction in mortality with ACE inhibitor and ARB over other antihypertensive agents. 76, 77 As a result of these data, both the European Society of Cardiology and ACC/AHA guidelines give a class II recommendation for ACE inhibitor or ARB for PAD. 15, 72 Nevertheless, a post hoc subanalysis of the ALL-HAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) and a prespecified subgroup analysis of VALUE (Valsartan Antihypertensive Long-Term Use Evaluation) did not show a significant reduction in primary end points of fatal or nonfatal MI and major adverse cardiovascular events, respectively, with ACE inhibitor or ARB over other antihypertensive classes in subgroup analysis of patients with symptomatic PAD. [78] [79] [80] Certainly, control of hypertension is an important facet to medical therapy in PAD, but it remains to be seen whether ACE inhibitor or ARB offer benefits beyond blood pressure control in PAD.
SMOKING CESSATION
Smoking is the single greatest modifiable risk factor for the development and progression of PAD. Tobacco smoke increases endothelial cell permeability by formation of reactive oxygen species, which enables atherosclerosis to settle within vessel walls. 81 The magnitude of this effect is clinically evident with the prevalence of PAD increased 2.3-fold in current smokers, by one systematic review. 82 The risk of incident PAD persists for ≤30 years even with cessation. 83 Patients with PAD experience smoking-related complications and increased mortality. In one registry of 739 patients with PAD who underwent angiography, those who continued smoking had increased mortality at follow-up to 5 years (31% versus 14%; P<0.05). In the same registry, amputation rate was also higher in survivors who continued to smoke (40% versus 19%; P<0.05). 84 Smoking fosters PAD and augments complication rates, and thus providers should focus on cessation.
Multidisciplinary efforts to intervene on smoking can be effective. In one randomized trial of 124 patients, an intensive intervention group, which included cognitive behavioral counseling, motivational interviewing, and pharmacological therapy, resulted in a significantly higher rate of cessation than verbal advice alone (21.3% versus 6.8%; P=0.023). 85 Even physician verbal advice alone has been associated with improved smoking cessation. 86 Pharmacological therapy for smoking cessation is recommended in patients with PAD to reduce cravings. Varenicline was assessed in 714 patients with stable cardiovascular disease including 179 patients with PAD. While there was not a subanalysis of this PAD group, patients taking varenicline did have higher rates of smoking cessation for the duration of the trial at 52 weeks (19.2% versus 7.2%; P<0.0001). There was no change in cardiovascular mortality or all-cause mortality between patients taking varenicline and placebo (cardiovascular mortality, 0.3% versus 0.6% [CI, 1.3-0.7]; all-cause mortality, 0.6% versus 1.4% [CI, 2.3-0.6]). 87 According to guidelines, bupropion is equivalent in efficacy to varenicline for smoking cessation purposes. 86 Nicotine replacement therapy is also recommended as a therapy to aid smoking cessation. A recent Cochrane Review on the safety and efficacy of 136 nicotine replacement therapy trials found that all varieties of nicotine replacement therapy (gum, patch, lozenge, spray) effectively increase the rate of cessation. Combined nicotine replacement therapy, for example, using a nicotine patch and gum, is also felt to be more effective than use of a single agent alone. Furthermore, while side effects of tachycardia and arrhythmia were more common with the use of nicotine replacement therapy than placebo, serious cardiovascular side effects such as stroke, MI, and cardiovascular death were not more common in nicotine replacement therapy groups. 86, 88 Though evidence is lacking for a direct reduction in PAD-related mortality with use of counseling or pharmacological therapy such as nicotine replacement therapy, bupropion, and varenicline, the impact these interventions can have on smoking cessation efforts was sufficient to codify these interventions as class IA recommendations for PAD patients. 15 
EXERCISE THERAPY
Plaque burden and endothelial dysfunction narrow and stiffen the arteries supplying lower extremity skeletal muscles in patients with PAD. The debilitating pain of claudication results from increased skeletal muscle demand for oxygen during exercise not met with adequate supply as a result of complex alterations in arterial physiology including changes in flow-mediated dilationa measure of endothelial function. [89] [90] [91] Exercise therapy is designed to address lifestyle limitations imposed by claudication symptoms of PAD.
A number of randomized trials have demonstrated improvement in functional capacity following exercise therapy, and as such, the ACC/AHA provides a class 1A recommendation for supervised therapy for patients with claudication. 15 A recent meta-analysis of exercise therapy trials found a mean difference of 82.11 m ([95% CI, 71.73-92.48] P<0.00001) in pain-free walking distance, in addition to improvements in quality-of-life metrics. 92 Meta-analysis also showed that supervised exercise therapy programs appear to be even more effective than home-based therapy with similar adherence rates. 93 The duration of benefit from exercise therapy is prolonged well beyond the completion of the program, ≤7 years following a 28-week supervised program. 94 Several studies have shown improvements in flow-mediated dilation following exercise therapy, but not all trials demonstrated success. [95] [96] [97] Exercise therapy does not have a clear effect on mortality or amputation rates. 92, 93 HEALTH DISPARITIES Special emphasis on the optimization of medical management for PAD should be placed on at-risk populations. In particular, blacks face elevated rates of PAD leading to high morbidity and mortality. 10, 11 The incidence of PAD among blacks remains strikingly high, ≈2 to 3× the rate of non-Hispanic whites at all age groups. This elevated incidence occurs in spite of a lower smoking rate in this population. 98, 99 Black race is one of the strongest risk factors for the development of PAD and remains so even when controlling for traditional cardiovascular risk factors (smoking, diabetes mellitus, and hypertension) and nontraditional inflammatory markers associated with cardiovascular disease (CRP, IL-6, D-dimer, fibrinogen, and homocysteine). 10, 11, 100, 101 Age-adjusted mortality for black men is higher than non-Hispanic whites and Hispanic men (24.8 versus 19.9 versus 15.4 per 100 000), and rates are similarly elevated for blacks above non-Hispanic whites and Hispanic women (16.5 versus 13.8 versus 10.7). 102, 103 Importantly, mobility loss secondary to PAD is also worse for blacks. 104 In addition, blacks are 2 to 4× more likely to undergo amputation when compared with non-Hispanic whites. 12, 105, 106 Furthermore, graft failure and amputation following bypass is more common in blacks, in particular, black women. 107 Management of PAD in blacks has been shown to be suboptimal. Although smoking is a significant risk factor for the development of PAD and its complications, smoking is the least successful factor modification in blacks. 108 Furthermore, blacks are more likely to attempt to quit than whites though less likely to succeed. 109 Though CLI is more common in the black population, blacks are less likely to be offered and to receive salvage revascularization attempts. [110] [111] [112] This could be due to a number of factors including unconscious bias and more advanced disease at time presentation. 113 Improvement of medical optimization in this population may mitigate the disparity in limb salvage rate. As of yet, medical management appears to be underutilized in blacks. Cholesterol-lowering therapies are less frequently prescribed in blacks even when indicated by the guidelines. 114, 115 Black women, in particular, appear to have even lower rates of guideline-based statin use. 116 On review of >23 000 PAD interventions, one study found that blacks were less likely to be on a statin before abdominal aortic aneurysm repair or PAD intervention. Furthermore, blacks were less likely to be discharged on combination statin and antiplatelet regimen after either abdominal aortic aneurysm repair or PAD intervention. 117 In addition to improving application of guideline-based therapy, nontraditional healthcare settings may improve delivery of care. A recent pharmacist-led intervention in predominantly black barbershops identified hypertensive adults and prescribed antihypertensives with excellent control in blood pressure and improved medication adherence. 118 Utilization of barbershops for identification and medical optimization of PAD in the black population is an emerging area of interest and may result in similarly improved control of blood pressure, as well as reduction in cholesterol, platelet activity, and coagulation. 119 
CONCLUSIONS
PAD is a devastating disease with high morbidity and high mortality. Though trials assessing effectiveness of medical interventions for PAD remain few in number, providers and patients alike should remain optimistic given the expanding number of available management strategies. Beyond medical therapy, ongoing trials such as BEST-CLI (Best Endovascular Versus Best Surgical Therapy for Patients With Critical Limb Ischemia) will provide insight into optimal interventional practices for patients with PAD. 120 A number of medical therapies exist to reduce cardiovascular mortality, as well as prevent progression, limb loss, and the need for invasive interventions. Cholesterol management includes not only high-intensity statin therapy but ezetimibe and PCSK9 inhibitors, all of which have the potential to reduce limb loss and improve cardiovascular outcomes. Antiplatelet therapy remains a cornerstone of PAD management with clopidogrel decreasing limb events, stroke, and MI even above aspirin. New to the repertoire of the treating provider, rivaroxaban adds to a growing list of effective medications possibly by addressing atherothromboembolism-a common source of complications in PAD. Cilostazol and ACE inhibitor continue to have a role in the management of select patients though evidence supporting their use for PAD is less robust. Patients with claudication symptoms can find symptomatic improvement with supervised exercise therapy. Finally, interventions to aid in smoking cessation such as counseling, nicotine replacement therapy, bupropion, and varenicline are effective and safe tools for risk factor modification. Despite the multitude of medical treatment options available, PAD is chronically undertreated relative to CAD. Future advancements in management strategies and improved application of available medical therapies will prevent complications and improve the quality of life for patients with PAD.
